Genentech paves path to increased clinical trial diversity as a ‘business imperative’
Genentech is aiming to lead the charge for clinical trial diversity in the pharma industry and it’s using a mix of regulatory commitments, trial site partnerships and community activism to get there.
Genentech has already filed 20 diversity action plans for Phase 3 studies with the FDA ahead of the agency’s final ruling, which it believes is the most in the industry. The FDA guidance is tied to the Food and Drug Omnibus Reform Act of 2022 (FDORA), which requires pharma companies to submit diversity action plans to the agency ahead of pivotal trials.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
